TABLE 1.
Scores on Cognitive Domains for 31 Patients With Schizophrenia During Crossover Treatment With Placebo and Two Doses of DMXB-Aa
| Score |
||||||||
|---|---|---|---|---|---|---|---|---|
| Domain of MATRICS | Baseline |
Placebo |
DMXB-A, 75 mg b.i.d. |
DMXB-A, 150 mg b.i.d. |
||||
| Consensus Cognitive Battery | Mean | SD | Mean | SD | Mean | SD | Mean | SD |
| Speed of processing | 40.1 | 9.0 | 44.1 | 7.8 | 44.2 | 11.8 | 43.3 | 9.5 |
| Attention/vigilance | 35.8 | 10.3 | 41.6 | 10.3 | 44.3 | 10.2 | 41.3 | 10.6 |
| Working memory | 43.2 | 10.4 | 47.2 | 10.9 | 47.6 | 12.1 | 46.5 | 9.8 |
| Verbal learning | 36.2 | 9.0 | 43.4 | 12.4 | 39.9 | 9.6 | 42.4 | 10.5 |
| Visual learning | 44.1 | 11.2 | 44.4 | 12.6 | 44.9 | 12.2 | 43.2 | 11.6 |
| Reasoning/problem solving | 44.0 | 8.9 | 49.1 | 9.6 | 48.6 | 8.7 | 46.7 | 9.0 |
a
No domain showed a significant effect of treatment over the three arms of treatment.